| Detailed information |
|---|
| CancerLivER ID | 2052 |
| Biomarker | EMA |
| Biomarker Name/Symbol (given in Publication) | EMA |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Biomarker for hypoxia in HCC and ICC tissues and validated on independent dataset |
| Experimental Condition | HCC v/s Normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated for CTCs in patients with HCC. |
| Level of significance | p < 0.05 |
| Source | Blood |
| PMID | 27034142 |
| Type of Biomarker | Diagnostic |
| Pathway | Cell adhesion and cell signaling |
| Cohort | 23 patients with HCC, two with cholangiocarcinoma (CC), one with combined HCC-CC, and three with metastatic carcinomas (two colorectal adenocarcinomas and one nasopharyngeal carcinoma) ; seven cell lines in cluding 6 HCC cell line i.e. HepG2, PLC/PRF5, and Huh-7 etc and two colon cancer cell lines |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |